Ipsen adds former Teva SVP and specialist in French-American HR to exec team

13 March 2018

French drugmaker Ipsen (Euronext: IPN) has added two new names to its executive leadership team.

Ivana Magovčević-Liebisch (above, left) has joined as chief business officer and Régis Mulot (right) has been named chief human resources officer.

Dr Magovčević-Liebisch joins Ipsen from US biotech Axcella Health, having been at Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) as head of global business development from 2013 to 2017. In total, she has 20 years of experience in biopharma with a combination of expertise in corporate partnering, M&A, pipeline and product portfolio development, legal and IP strategy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK